R&G PharmaStudies Co. Ltd. A (301333.SZ) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · China · ISIN CNE100005K44
R&G PharmaStudies Co. Ltd. A financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 744.00 m CNY | 851.01 m CNY |
| Gross profit | 275.92 m CNY | 295.64 m CNY |
| Operating income | 130.49 m CNY | 135.02 m CNY |
| EBIT | 161.23 m CNY | 158.01 m CNY |
| Net income | 140.22 m CNY | 136.90 m CNY |
| Diluted EPS – continuing operations | 1.45 CNY | 1.42 CNY |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About R&G PharmaStudies Co. Ltd. A
R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It offers drug clinical research and development integrated services. The company's services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology services. It serves pharmaceutical and medical device companies, and scientific research institutions. The company was founded in 2008 and is headquartered in Beijing, China.
More stocks
- JM AB (JM.ST)
- First Watch Restaurant Group, Inc. (FWRG)
- Zhejiang Goldensea Envi Tech C (603311.SS)
- Anhui Landun Photoelectron Co Ltd (300862.SZ)
- Jilin Expressway Co Ltd (601518.SS)
- Cendes Co Ltd Class A (300492.SZ)
- Jaya Real Property Tbk (JRPT.JK)
- Ottogi (007310.KS)
- GFT Technologies (GFT.DE)
- Kuros Biosciences AG (KURN.SW)
- Basler (BSL.DE)
- Jiangxi Black Cat Carbon Black (002068.SZ)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.